Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Bioceros announces license option agreement with MaimoniDex RA
for antibodies to be used for treatment of rheumatoid arthritis


Press release of MaimoniDex RA Ltd. and Bioceros BV

Utrecht, The Netherlands – January 7, 2008

Biotechnology company Bioceros BV and antibody company Maimonidex RA Ltd. announce today they will start a collaboration on the development of a monoclonal antibody specific for CD44vRA, a splice variant of the adhesion molecule CD44, involved in the inflammatory process underlying Rheumatoid Arthritis (RA). Bioceros will be granted an option to a world-wide exclusive license on the intellectual property and technology owned by MaimoniDex.

MaimoniDex is an Israeli biotech company focused on discovering disease-specific targets for a variety of major diseases. MaimoniDex's core business is the treatment of RA with disease specific anti-CD44vRA monoclonal antibodies. Treatment of CD44vRA expressing synovial cells with these antibodies results in apoptosis of the activated synovial cells. CD44vRA is not expressed on normal tissues of the same patients and therefore this approach represents the first therapy specifically targeting RA at the site of the harmful inflammation.

In addition to its product portfolio, Bioceros offers services to customers on generation of high protein producing mammalian (CHO based) cell lines and process development. Bioceros’ Chief Executive Officer, Bram Bout, said: “This deal is in line with our strategy to expand our product portfolio with high potential monoclonal antibodies from top-experts in the field and which we can leverage through our technology platform”.

“Working with Bioceros, with an excellent track record of successful partnerships, will enable the production of a commercially viable humanized monoclonal antibody for treating RA. We are confident that their experience and professional abilities can deliver a superior product in a timely manner. We are pleased to collaborate with Bioceros in the development of the first specific drug for RA', said Dr. Itshak Golan, President and Chief Executive Officer of MaimoniDex.

Financial terms of the collaboration were not disclosed.

For further information, visit www.bioceros.com or contact:

MaimoniDex RA Ltd.:
Dr. Itshak Golan (CEO)
23 Gainsborough Garden
Golders Green, London NW11 9BJ
United Kingdom
tel. +44 77 9123 5930
i.golan@imperial.ac.uk

Bioceros BV:
Remco M. Brandt, M.Sc. (COO)
Yalelaan 46
3584 CM Utrecht
The Netherlands
tel. +31 30-253 7910
r.brandt@bioceros.com


Publisher Contact Information:

Bioceros
+31 30-253 7910
r.brandt@bioceros.com

Company profile of Bioceros (acquired by Epirus)
Past press releases of Bioceros (acquired by Epirus).

Data


26,368
Tech investments
From our Online Data Service
17,022
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 15€2.4MMaterials
Nov 15€6.0MArtificial Intelligence
Nov 15€3.5MSoftware development
Nov 15N/AInternet services
Nov 14€4.5MOther Software
Nov 14€4.7MBusiness applications
Nov 14€9.0MKnowledge management

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.